Related Experiment Video
Updated: Jun 17, 2025
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting
Wanlong Lin1, Yanbin Zeng1, Lizhu Weng1
1Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, 10# Zhenhai Road, Xiamen, China.
Background:
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors marked a milestone in the breast cancer treatment. Due to the potential impact of adverse effects on treatment decisions and patient outcomes, careful consideration of the varying toxicities of CDK4/6 inhibitors is crucial, as three inhibitors-palbociclib, abemaciclib, and ribociclib-have been approved with differences in adverse event profiles. However, limitations in clinical trials call for urgent real-world safety studies to evaluate and compare the risk of adverse events (AEs) among these CDK4/6 inhibitors. Therefore, this study aimed to analyze AEs of CDK4/6 inhibitors and provide insights for clinical drug selection, using real world database.
Methods:
The AEs of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (2015-2022) were analyzed. Four disproportionality methods were used to detect safety signals: reporting odds ratio (ROR), proportional reporting ratio, Bayesian Confidence Neural Network Propagation, and Multi-Item Gamma Poisson Shrinker. Venn analysis was used to compare and select common and specific AEs.
Results:
This study included 73,042 patients treated with palbociclib, 25,142 with ribociclib, and 7563 with abemaciclib. All three inhibitors had 27 common AEs. Palbociclib exhibited the highest ROR for hematologic toxicities, while ribociclib showed the highest ROR for macrocytosis, nail disorders, and hepatic lesions. Abemaciclib displayed the highest ROR for mucosal toxicity. Common signals for both palbociclib and ribociclib included hematologic toxicities, decreased immune responsiveness, and aphthous ulcers. Myelosuppression, oral pain, and pseudocirrhosis were common signals for palbociclib and abemaciclib. Anemia, hepatotoxicity, and pneumonitis were observed as common signals for ribociclib and abemaciclib. Furthermore, specific AEs associated with palbociclib included fatigue, alopecia, and stomatitis. For ribociclib, specific AEs included electrocardiogram QT prolongation, thrombocytopenia, and decreased hemoglobin. Abemaciclib was specifically linked to diarrhea, vomiting, and interstitial lung disease.
Conclusion:
Our analysis revealed that palbociclib showed a higher risk of hematologic toxicity. Ribociclib showed higher risks of hepatotoxicity, nephrotoxicity, and QT prolongation. Abemaciclib showed higher risks of hepatotoxicity, gastrointestinal effects, interstitial lung disease, and thrombosis. These findings provide valuable insights for CDK4/6 inhibitor selection.
Insights
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have varying safety profiles in breast cancer treatment. Palbociclib risks hematologic toxicity, ribociclib risks hepatotoxicity and QT prolongation, and abemaciclib risks gastrointestinal effects and interstitial lung disease.
Area of Science:
- Oncology
- Pharmacology
- Clinical Research
Background:
- Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors represent a significant advancement in breast cancer therapy.
- Understanding the distinct adverse event (AE) profiles of palbociclib, abemaciclib, and ribociclib is crucial for optimizing patient outcomes.
- Real-world safety data are needed to complement clinical trial findings on CDK4/6 inhibitor toxicities.
Purpose of the Study:
- To analyze and compare the adverse event profiles of three approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib.
- To identify common and specific safety signals associated with each CDK4/6 inhibitor using real-world data.
- To provide evidence-based insights for informed clinical selection of CDK4/6 inhibitors.
Main Methods:
- Analysis of AE data from the FDA Adverse Event Reporting System (FAERS) between 2015 and 2022.
- Utilized four disproportionality methods (ROR, PRR, BNNP, MGPS) for robust safety signal detection.
- Employed Venn analysis to compare and delineate common and unique AEs across the three inhibitors.
Main Results:
- The study included a large cohort: 73,042 patients on palbociclib, 25,142 on ribociclib, and 7,563 on abemaciclib.
- Palbociclib showed the highest risk for hematologic toxicities; ribociclib for macrocytosis, nail disorders, and hepatic lesions; abemaciclib for mucosal toxicity.
- Specific AEs included QT prolongation for ribociclib and interstitial lung disease for abemaciclib, while palbociclib was associated with hematologic toxicities.
Conclusions:
- Palbociclib is associated with a higher risk of hematologic toxicity.
- Ribociclib demonstrates increased risks of hepatotoxicity, nephrotoxicity, and QT prolongation.
- Abemaciclib is linked to elevated risks of hepatotoxicity, gastrointestinal issues, interstitial lung disease, and thrombosis, guiding clinical drug selection.
Related Concept Videos
02:34Inhibition of Cdk Activity
01:20Comparing the Survival Analysis of Two or More Groups
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:12Hazard Ratio
For example, in a clinical trial...